Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center